Phase Ib/II study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER plus ) breast cancer or advanced solid tumors

被引：0
|
作者：
Kalinsky, Kevin
Tolcher, Anthony W.
Wang, Shushen
Meric-Bernstam, Funda
Winkler, Robert
Li, Mingyu
Sun, Xuemei
Pan, Wentao
Paudyal, Bishnuhari
Liang, Zhiyan
Lu, Ming
Yang, Dajun
Zhai, Yifan
机构：
[1] Emory Univ, Winship Canc Inst, Glenn Family Breast Ctr, Dept Hematol & Med Oncol, Atlanta, GA USA
[2] Emory Univ, Winship Canc Inst, Breast Med Oncol, Atlanta, GA USA
[3] NEXT Oncol & Texas Oncol, San Antonio, TX USA
[4] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou, Peoples R China
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[6] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS1122
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Time to Chemotherapy for Patients With Estrogen Receptor-Positive Breast Cancer and Cyclin-Dependent Kinase 4 and 6 Inhibitor Use
    Endo, Yuka
    Yoshimura, Akiyo
    Sawaki, Masataka
    Hattori, Masaya
    Kotani, Haruru
    Kataoka, Ayumi
    Horisawa, Nanae
    Ozaki, Yuri
    Nozawa, Kazuki
    Takatsuka, Daiki
    Isogai, Ayaka
    Iwata, Hiroji
    JOURNAL OF BREAST CANCER, 2022, 25 (04) : 296 - 306
  • [2] A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer
    Zhang, Pin
    Xu, Binghe
    Gui, Lin
    Wang, Wenna
    Xiu, Meng
    Zhang, Xiao
    Sun, Guilan
    Zhu, Xiaoyu
    Zou, Jianjun
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [3] A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer
    Pin Zhang
    Binghe Xu
    Lin Gui
    Wenna Wang
    Meng Xiu
    Xiao Zhang
    Guilan Sun
    Xiaoyu Zhu
    Jianjun Zou
    Biomarker Research, 9
  • [4] NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
    Ma, Cynthia X.
    Gao, Feng
    Luo, Jingqin
    Northfelt, Donald W.
    Goetz, Matthew
    Forero, Andres
    Hoog, Jeremy
    Naughton, Michael
    Ademuyiwa, Foluso
    Suresh, Rama
    Anderson, Karen S.
    Margenthaler, Julie
    Aft, Rebecca
    Hobday, Timothy
    Moynihan, Timothy
    Gillanders, William
    Cyr, Amy
    Eberlein, Timothy J.
    Hieken, Tina
    Krontiras, Helen
    Guo, Zhanfang
    Lee, Michelle V.
    Spies, Nicholas C.
    Skidmore, Zachary L.
    Griffith, Obi L.
    Griffith, Malachi
    Thomas, Shana
    Bumb, Caroline
    Vij, Kiran
    Bartlett, Cynthia Huang
    Koehler, Maria
    Al-Kateb, Hussam
    Sanati, Souzan
    Ellis, Matthew J.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4055 - 4065
  • [5] Fulvestrant with or without the cyclin-dependent kinase 7 (CDK7) inhibitor samuraciclib in advanced hormone receptor positive (HR plus ) breast cancer after CDK4/6 inhibition: Phase II SUMIT-BC study
    Pernas, Sonia
    Hinojo, Carmen
    Pascual, Javier
    Aksoy, Sercan
    Clack, Glen
    McIntosh, Stuart
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR plus ) metastatic breast cancer (MBC): Phase Ib study results.
    Zhang, Jian
    Meng, Yanchun
    Wang, Biyun
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Yao, Wenqing
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive metastatic breast cancer
    Xu, Ting
    Zhang, Lili
    Yuan, Yuan
    Hu, Sainan
    Dong, Min
    Xu, Xinyu
    Huang, Jiayuan
    Xiong, Weili
    Lou, Kexin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive Metastatic Breast Cancer
    Xu, Ting
    Xiong, Weili
    Zhang, Lili
    Yuan, Yuan
    BREAST JOURNAL, 2024, 2024
  • [9] Dalpiciclib. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Treatment of HR+/HER2-and HER2+advanced breast cancer
    Wang, Jingru
    Dong, Xiaotong
    Ashby, Charles R.
    Chen, Zhe-Sheng
    Zhang, Yunxiang
    DRUGS OF THE FUTURE, 2022, 47 (12) : 867 - 886
  • [10] VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor (CDK4/6i)-resistant advanced solid tumors
    Yap, Timothy
    Patel, Manish
    Henick, Brian
    Moore, Kathleen
    Leary, Alexandra
    Do, Doreen
    Chapman, Josh
    Zhang, Hui
    Roche, Maria
    Newberry, Kate
    Rinne, Mikael
    Juric, Dejan
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S173 - S173
12345